User login
Psoriasis Therapy During the COVID-19 Pandemic: Should Patients Continue Biologics?
5 Key Points on Dietary Counseling of Acne Patients
PsA Fast Facts: Symptoms
PsA Fast Facts: Prevalence and incidence
Don’t miss early joint involvement in psoriasis
WAIKOLOA, HAWAII – advised Alan Menter, MD.
About a third of patients with psoriasis will go on to develop joint involvement, and about half of those will go on to develop permanent joint destruction “if left untreated,” he noted. But early joint involvement has to be caught first, and dermatologists aren’t doing a very good job at early detection, according to Dr. Menter, clinical professor of dermatology at the University of Texas, Dallas.
The consequences, including arthritis mutilans, can be devastating. “It’s vitally important for us to prevent any permanent joint disease by” picking it up early, he said. “Our job as dermatologists is to diagnose it early.”
It’s not hard to do, just a few extra questions and a few extra steps on the physical exam, which takes a minute or two during each visit with psoriasis patients, are needed, he said.
Dr. Menter reviewed questions to ask patients, and explained how to examine patients for joint involvement and alter treatment when it’s found, in an interview at the Hawaii Dermatology Seminar provided by Global Academy for Medical Education/Skin Disease Education Foundation.
SDEF/Global Academy for Medical Education and this news organization are owned by the same parent company.
WAIKOLOA, HAWAII – advised Alan Menter, MD.
About a third of patients with psoriasis will go on to develop joint involvement, and about half of those will go on to develop permanent joint destruction “if left untreated,” he noted. But early joint involvement has to be caught first, and dermatologists aren’t doing a very good job at early detection, according to Dr. Menter, clinical professor of dermatology at the University of Texas, Dallas.
The consequences, including arthritis mutilans, can be devastating. “It’s vitally important for us to prevent any permanent joint disease by” picking it up early, he said. “Our job as dermatologists is to diagnose it early.”
It’s not hard to do, just a few extra questions and a few extra steps on the physical exam, which takes a minute or two during each visit with psoriasis patients, are needed, he said.
Dr. Menter reviewed questions to ask patients, and explained how to examine patients for joint involvement and alter treatment when it’s found, in an interview at the Hawaii Dermatology Seminar provided by Global Academy for Medical Education/Skin Disease Education Foundation.
SDEF/Global Academy for Medical Education and this news organization are owned by the same parent company.
WAIKOLOA, HAWAII – advised Alan Menter, MD.
About a third of patients with psoriasis will go on to develop joint involvement, and about half of those will go on to develop permanent joint destruction “if left untreated,” he noted. But early joint involvement has to be caught first, and dermatologists aren’t doing a very good job at early detection, according to Dr. Menter, clinical professor of dermatology at the University of Texas, Dallas.
The consequences, including arthritis mutilans, can be devastating. “It’s vitally important for us to prevent any permanent joint disease by” picking it up early, he said. “Our job as dermatologists is to diagnose it early.”
It’s not hard to do, just a few extra questions and a few extra steps on the physical exam, which takes a minute or two during each visit with psoriasis patients, are needed, he said.
Dr. Menter reviewed questions to ask patients, and explained how to examine patients for joint involvement and alter treatment when it’s found, in an interview at the Hawaii Dermatology Seminar provided by Global Academy for Medical Education/Skin Disease Education Foundation.
SDEF/Global Academy for Medical Education and this news organization are owned by the same parent company.
EXPERT ANALYSIS FROM SDEF HAWAII DERMATOLOGY SEMINAR
(Sponsored) Video Roundtable: Basal Insulin Pharmacology
Pharmacokinetic (PK) and pharmacodynamic (PD) properties of drugs form the basis for the development of drugs used in everyday clinical practice, such as commonly used insulin products. PK measures the concentration of a drug in the body, and reflects the rates and amounts absorbed and processed. PD is the biologic effect of a drug in the body, including the time-course of when the biologic effect starts, peaks, and ends. While the determination of PK/PD parameters is important and foundational for the development of different insulin products, studies are often complex and can be difficult to translate into real-world clinical practice. In this roundtable, the speakers discuss PK/PD concepts, focusing on the differentiation of basal insulin analogs and their use in individualized diabetes therapy.
First, the speakers discuss the euglycemic glucose clamp methodology—the standard technique for evaluating PK/PD of insulin—including how it is performed, what parameters it measures (and how they can be interpreted), and its limitations.
Next, the speakers discuss how PK/PD impacts drug development, with particular focus on PK/PD studies used in the development of the second-generation basal insulin analogs insulin glargine 300 U/mL (Gla-300) and insulin degludec.
Finally, the speakers discuss how PK/PD data translate into clinical practice, including the relationship between PK/PD and drug efficacy and safety, and how it influences dosing strategies, hypoglycemia risk, and patient education. Further, the speakers discuss how the PK/PD profile of basal insulins can inform primary care providers when selecting appropriate individualized therapy for patients.
Financial support provided by Sanofi US, Inc.
Pharmacokinetic (PK) and pharmacodynamic (PD) properties of drugs form the basis for the development of drugs used in everyday clinical practice, such as commonly used insulin products. PK measures the concentration of a drug in the body, and reflects the rates and amounts absorbed and processed. PD is the biologic effect of a drug in the body, including the time-course of when the biologic effect starts, peaks, and ends. While the determination of PK/PD parameters is important and foundational for the development of different insulin products, studies are often complex and can be difficult to translate into real-world clinical practice. In this roundtable, the speakers discuss PK/PD concepts, focusing on the differentiation of basal insulin analogs and their use in individualized diabetes therapy.
First, the speakers discuss the euglycemic glucose clamp methodology—the standard technique for evaluating PK/PD of insulin—including how it is performed, what parameters it measures (and how they can be interpreted), and its limitations.
Next, the speakers discuss how PK/PD impacts drug development, with particular focus on PK/PD studies used in the development of the second-generation basal insulin analogs insulin glargine 300 U/mL (Gla-300) and insulin degludec.
Finally, the speakers discuss how PK/PD data translate into clinical practice, including the relationship between PK/PD and drug efficacy and safety, and how it influences dosing strategies, hypoglycemia risk, and patient education. Further, the speakers discuss how the PK/PD profile of basal insulins can inform primary care providers when selecting appropriate individualized therapy for patients.
Financial support provided by Sanofi US, Inc.
Pharmacokinetic (PK) and pharmacodynamic (PD) properties of drugs form the basis for the development of drugs used in everyday clinical practice, such as commonly used insulin products. PK measures the concentration of a drug in the body, and reflects the rates and amounts absorbed and processed. PD is the biologic effect of a drug in the body, including the time-course of when the biologic effect starts, peaks, and ends. While the determination of PK/PD parameters is important and foundational for the development of different insulin products, studies are often complex and can be difficult to translate into real-world clinical practice. In this roundtable, the speakers discuss PK/PD concepts, focusing on the differentiation of basal insulin analogs and their use in individualized diabetes therapy.
First, the speakers discuss the euglycemic glucose clamp methodology—the standard technique for evaluating PK/PD of insulin—including how it is performed, what parameters it measures (and how they can be interpreted), and its limitations.
Next, the speakers discuss how PK/PD impacts drug development, with particular focus on PK/PD studies used in the development of the second-generation basal insulin analogs insulin glargine 300 U/mL (Gla-300) and insulin degludec.
Finally, the speakers discuss how PK/PD data translate into clinical practice, including the relationship between PK/PD and drug efficacy and safety, and how it influences dosing strategies, hypoglycemia risk, and patient education. Further, the speakers discuss how the PK/PD profile of basal insulins can inform primary care providers when selecting appropriate individualized therapy for patients.
Financial support provided by Sanofi US, Inc.
Bradycardia guidelines, hypertension’s risk in young adults, and more
This week on Cardiocast, guidelines for bradycardia set a new bar for shared decision-making in pacemaker placement, young adults with hypertension may be at higher CVD risk, how sleep quality affects cardiovascular risk, and a strong showing for exercise in patients with both heart failure and sleep apnea.
Tune in next Friday for the most exciting news from the scientific sessions of the American Heart Association, as told by the reporters who cover it.
Subscribe to Cardiocast wherever you get your podcasts.
This week on Cardiocast, guidelines for bradycardia set a new bar for shared decision-making in pacemaker placement, young adults with hypertension may be at higher CVD risk, how sleep quality affects cardiovascular risk, and a strong showing for exercise in patients with both heart failure and sleep apnea.
Tune in next Friday for the most exciting news from the scientific sessions of the American Heart Association, as told by the reporters who cover it.
Subscribe to Cardiocast wherever you get your podcasts.
This week on Cardiocast, guidelines for bradycardia set a new bar for shared decision-making in pacemaker placement, young adults with hypertension may be at higher CVD risk, how sleep quality affects cardiovascular risk, and a strong showing for exercise in patients with both heart failure and sleep apnea.
Tune in next Friday for the most exciting news from the scientific sessions of the American Heart Association, as told by the reporters who cover it.
Subscribe to Cardiocast wherever you get your podcasts.
A new MI risk factor emerges, ASCVD guidelines challenged, and more
Today, an analysis that may challenge ASCVD guidelines, a new formula may predict adverse events from NSAIDs, a potentially important myocardial infarction risk factor is identified, and a diabetes drug gets a new cardiovascular indication.
Subscribe to Cardiocast wherever you get your podcasts.
Amazon Alexa
Apple Podcasts
Today, an analysis that may challenge ASCVD guidelines, a new formula may predict adverse events from NSAIDs, a potentially important myocardial infarction risk factor is identified, and a diabetes drug gets a new cardiovascular indication.
Subscribe to Cardiocast wherever you get your podcasts.
Amazon Alexa
Apple Podcasts
Today, an analysis that may challenge ASCVD guidelines, a new formula may predict adverse events from NSAIDs, a potentially important myocardial infarction risk factor is identified, and a diabetes drug gets a new cardiovascular indication.
Subscribe to Cardiocast wherever you get your podcasts.
Amazon Alexa
Apple Podcasts
Novel blood test for RA prevention?
Also today, radiation to survival of metastatic cancer, cannabis crimps teen cognitive development, bipolar patients’ relatives face increased cardiovascular risk. Amazon Alexa
Apple Podcasts
Spotify
Also today, radiation to survival of metastatic cancer, cannabis crimps teen cognitive development, bipolar patients’ relatives face increased cardiovascular risk. Amazon Alexa
Apple Podcasts
Spotify
Also today, radiation to survival of metastatic cancer, cannabis crimps teen cognitive development, bipolar patients’ relatives face increased cardiovascular risk. Amazon Alexa
Apple Podcasts
Spotify
